KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Alnylam Pharmaceuticals (ALNY) Invested Capital (2016 - 2025)

Alnylam Pharmaceuticals' Invested Capital history spans 17 years, with the latest figure at $789.2 million for Q4 2025.

  • For Q4 2025, Invested Capital rose 390.57% year-over-year to $789.2 million; the TTM value through Dec 2025 reached $789.2 million, up 390.57%, while the annual FY2025 figure was $789.2 million, 390.57% up from the prior year.
  • Invested Capital reached $789.2 million in Q4 2025 per ALNY's latest filing, up from $355.2 million in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $1.3 billion in Q2 2021 to a low of -$408.1 million in Q2 2023.
  • Average Invested Capital over 5 years is $361.5 million, with a median of $197.2 million recorded in 2024.
  • Peak YoY movement for Invested Capital: tumbled 147.8% in 2023, then skyrocketed 12208.87% in 2025.
  • A 5-year view of Invested Capital shows it stood at $1.3 billion in 2021, then crashed by 112.52% to -$158.2 million in 2022, then tumbled by 39.45% to -$220.6 million in 2023, then skyrocketed by 172.91% to $160.9 million in 2024, then surged by 390.57% to $789.2 million in 2025.
  • Per Business Quant, the three most recent readings for ALNY's Invested Capital are $789.2 million (Q4 2025), $355.2 million (Q3 2025), and $371.4 million (Q2 2025).